AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00635232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules once daily for 12 weeks
Study NCT00635232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 200 mg (2 x 100 mg capsules) once daily for 12 weeks
Study NCT00635232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 400 mg (4 x 100 mg capsules) once daily for 12 weeks
Study NCT00635232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS433540
Description: 800 mg (8 x 100 mg capsules) once daily for 12 weeks
Study NCT03558178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Doin with acupuncture
Description: Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
Study NCT03558178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
Study NCT03558178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
Study NCT01184300 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
Description: Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
Study NCT02385513 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-valent pneumococcal conjugate vaccine
Study NCT00810238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Cure
Description: Intraventricular injection
Study NCT01818232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LX4211
Study NCT00680706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine (100 mg) in 50 ml D5W, x 2.
Study NCT00680706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5W (50 ml)
Study NCT01172431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide
Description: Indapamide SR 1.5mg qd
Study NCT01172431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg qd
Study NCT01866930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda-1a
Study NCT01866930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV)
Study NCT06016036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951
Description: SAL-0951：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study NCT06016036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAL-0951 placebo：~1. initial phase：4mg QD for 8 weeks~2. subsequent phase：1mg、2mg、4mg、6mg、8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study NCT01866930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribasphere (RBV)
Study NCT02967835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-psychiatry consult
Description: tele-psychiatry consult for evaluation and treatment recommendations
Study NCT04051073 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous non-invasive blood pressure monitoring
Description: Continuous non-invasive blood pressure monitoring using CNAP
Study NCT04051073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous non-invasive blood pressure monitoring
Description: Continuous non-invasive blood pressure monitoring using CNAP
Study NCT00775294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
Study NCT00205179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novasoy
Description: 100mg/day soy isoflavones
Study NCT01405742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rF.VIII
Description: 40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
Study NCT00205179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mg/day matching placebo
Study NCT00471328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 400 mg twice daily (bid)
Study NCT00471328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 400 mg twice daily (bid)
Study NCT00471328 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care (BSC) +/- imatinib or sunitinib
Description: Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
Study NCT02854631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selonsertib
Description: 18 mg tablet administered orally once daily
Study NCT02854631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: 40 mg (4 x 10 mg tablets) administered orally once daily
Study NCT02854631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 40 mg (4 x 10 mg tablets) administered orally once daily
Study NCT02586090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parents as Coaches
Description: PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
Study NCT02586090 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Weight Loss
Description: In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
Study NCT02247375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIIL 284 BS tablets
Study NCT02247375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIIL 284 BS tablets
Study NCT02247375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02755259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Study NCT02755259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03741049 — intervention group
Intervention type: DEVICE
Intervention: Scalpel Bougie technique (plastic laryngeal model)
Description: ScalpelBougie Set
Study NCT03741049 — intervention group
Intervention type: DEVICE
Intervention: Seldinger technique (plastic laryngeal model)
Description: Melker Set
Study NCT03053401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimuplex A needle
Description: 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
Study NCT03053401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
Study NCT03053401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
Study NCT04830059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of exercise intervention and control group
Study NCT04830059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purification
Description: Air purification in order to reduce the PM2.5 and PM10
Study NCT03741049 — intervention group
Intervention type: DEVICE
Intervention: Surgical technique (plastic laryngeal model)
Description: Scalpel and speculum
Study NCT05775952 — intervention group
Intervention type: BIOLOGICAL
Intervention: HRV-39
Description: We will use a US Food and Drug Administration (FDA) approved Good Manufacturing Practices (GMP)-grade HRV-39 for our proposed study. Use of this GMP-grade HRV-39 viral stock ensures compliance with recent regulatory agency requirements which, beginning in 2001, have mandated that HRV preparations used for human inoculation be made under Good Manufacturing Practices (GMP). This proposed clinical study will allow us to address fundamental questions regarding the nature, kinetics and potential mechanisms of upper and lower airway inflammatory responses in subjects with well-controlled mild-moderate asthma and in healthy, non-asthmatic control subjects; a better understanding of these mechanisms may lead to new paradigms in the treatment of virally-induced airway remodeling and asthma exacerbations.
Study NCT01560650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRRT
Description: Difference dose of CRRT
Study NCT03782909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Description: The behaviour change intervention consists of;~1. Feedback via an app based food diary~2. Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it
Study NCT02188186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initial triple combination
Description: Initial triple combination arm
Study NCT02188186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventioanl treament with dose escalation
Study NCT03678285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIFRT Workout
Description: A single high intensity functional resistance training (HIFRT) exercise bout.
Study NCT02346266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMART Education
Study NCT02527538 — intervention group
Intervention type: DEVICE
Intervention: Pleth
Description: apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
Study NCT01258712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab + methotrexate(MTX)
Description: Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
Study NCT01258712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab placebo + methotrexate(MTX)
Description: Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
Study NCT02602600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: * Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~* Weight maintenance diet for 2 weeks
Study NCT03404219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivation and Skills Support (MASS)
Description: Mobile phone-based application to support social skills and social motivation
Study NCT01072240 — intervention group
Intervention type: DRUG
Intervention: rituximab [Mabthera/Rituxan]
Description: As prescribed by physician
Study NCT00732238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened course of antibiotic therapy
Description: By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
Study NCT00858481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spinosad Creme Rinse - Vehicle Control
Description: One or two, 10-minute topical applications (7 days apart)
Study NCT00858481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinosad Creme Rinse
Description: 0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
Study NCT03741049 — intervention group
Intervention type: DEVICE
Intervention: Scalpel Bougie technique (porcine laryngeal model)
Description: ScalpelCric Set
Study NCT03741049 — intervention group
Intervention type: DEVICE
Intervention: Surgical technique (porcine laryngeal model)
Description: Scalpel and speculum
Study NCT00622856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological intervention
Description: Psychological intervention
Study NCT00858481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinosad Creme Rinse
Description: 1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
Study NCT00858481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinosad Creme Rinse
Description: 2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
Study NCT00990860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
Study NCT00990860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE (Transcatheter arterial chemoembolization)
Description: TACE (Transcatheter arterial chemoembolization)
Study NCT02750748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study NCT00732238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
Study NCT02750748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravail
Study NCT03555006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dual ultrasound reading local vs remote
Description: The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
Study NCT03555006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dual ultrasound reading local vs local
Description: The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
Study NCT05050110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fruits and Vegetable increase
Description: Increase fruits and vegetable consumption in chronic Kidney Patients to maintain Normokalemia
Study NCT03429400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine Sulfate
Description: Morphine every 4 hours as needed for up to a maximum of 5 days
Study NCT01507363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
Study NCT01507363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
Study NCT01507363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for 7 days, starting on the day of surgery
Study NCT00800007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANZ-521
Description: 3x10\^7 cfu or 3x10\^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
Study NCT00622856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: 5 sessions with diabetes nurse
Study NCT00681291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair with Ultrapro
Description: surgical mesh (15x15cm) to support Lichtenstein repair
Study NCT00874536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid alpha-linolenic acid (ALA)
Description: 3 grams of ALA-containing plant oil
Study NCT00874536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00891631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSBIRT
Description: Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
Study NCT00891631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSBIRT/TE
Description: Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
Study NCT00800007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
Study NCT02755077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head rotation during mask ventilation
Description: Patient's head position is axially rotated 45 degrees to the right.
Study NCT02897583 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: YAG vitreolysis
Study NCT02897583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: YAG vitreolysis
Study NCT01715792 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
Study NCT00850434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified AutoSet Algorithm
Description: The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm
Study NCT00850434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified AutoSet Algorithm
Description: The modified AutoSet algorithm responds to more patient non-normal flow types than the standard AutoSet algorithm
Study NCT00850434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard AutoSet Algorithm
Description: The standard AutoSet used for treatment of OSA
Study NCT00850434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard AutoSet Algorithm
Description: The standard AutoSet used for treatment of OSA
Study NCT04351828 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw once a time
Description: Investigation of intestinal permeability by measuring serum zonulin levels in blood sample
Study NCT04467671 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tissue Engineered Vascular Grafts
Description: Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
Study NCT00681291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair with Strattice
Description: Surgical mesh (10x16) used to support Lichtenstein repair
Study NCT00544466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m2 day -7 through day -3 prior to transplant
Study NCT00623194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
Study NCT00623194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
Study NCT02059538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Adipose tissue biopsies (omental and subcutaneous) liver
Study NCT02059538 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CT-scan
Study NCT02059538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stools sampling
Study NCT02059538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DNA sampling
Study NCT02059538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Study NCT02059538 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine sampling
Study NCT00513279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK618334
Description: GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.